Form 4: Glaukos CDO Navratil Acquires Shares via RSU Vesting

Glaukos Chief Development Officer Tomas Navratil acquired 1,948 shares of common stock through restricted stock unit vesting after achieving operational targets, while also disposing of 510 shares for tax obligations.

Summary

• Tomas Navratil, Chief Development Officer of Glaukos Corp, acquired 1,948 shares of common stock on September 18, 2025.
• These shares represent a portion of a restricted stock unit (RSU) award granted on March 18, 2021, which vested due to the achievement of pre-determined operational targets.
• The Compensation, Nominating & Governance Committee confirmed the achievement of two operational targets on September 18, 2025.
• 50% of these 1,948 shares will be delivered on September 23, 2025, with the remaining 50% delivered in June 2026.
• Navratil also disposed of 510 shares of common stock on September 19, 2025, at a price of $83.47 per share.
• This disposition was to cover tax withholding obligations related to the vesting and delivery of other restricted stock units granted on March 24, 2022.
• Following these transactions, Navratil beneficially owns 76,907 shares, which includes 43,509 unvested restricted stock units.

Sentiment

Score: 7

Explanation: The vesting of restricted stock units due to the achievement of operational targets is a positive indicator of company performance and management alignment. The subsequent sale for tax purposes is a routine event and does not detract significantly from the overall positive signal of performance-based compensation.

Positives

• Vesting of 1,948 restricted stock units indicates the achievement of pre-determined operational targets by Glaukos Corp.
• The Compensation, Nominating & Governance Committee confirmed the achievement of two operational targets, reflecting positive company performance.

Negatives

• Disposition of 510 shares for tax withholding purposes, though a standard practice, reduces the direct beneficial ownership of the reporting person.

Future Outlook

The filing indicates future delivery of vested shares, with 50% of the 1,948 shares expected by September 23, 2025, and the remaining 50% by June 2026. This suggests a continued long-term incentive structure for the Chief Development Officer.

Industry Context

This filing reflects standard executive compensation practices within the medical technology or pharmaceutical industry, where restricted stock units are commonly used to align executive incentives with long-term company performance and shareholder value. The vesting tied to operational targets is a common mechanism to reward specific achievements.

Related Party Transactions

• Acquisition of 1,948 shares of common stock by Tomas Navratil, Chief Development Officer, through the vesting of restricted stock units granted by Glaukos Corp.
• Disposition of 510 shares of common stock by Tomas Navratil to Glaukos Corp for tax withholding obligations related to RSU vesting.

Stakeholder Impact

• Shareholders: The vesting of performance-based RSUs suggests that management is meeting operational targets, which could be viewed positively as it aligns executive incentives with company performance. The tax-related sale is a routine event.
• Employees: The successful vesting of RSUs for a key executive may signal a healthy performance culture and the achievement of company goals.

Next Steps

• Delivery of 974 shares (50% of 1,948) to Tomas Navratil on September 23, 2025.
• Delivery of the remaining 974 shares (50% of 1,948) to Tomas Navratil in June 2026.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units due to achieved operational targets and subsequent tax-related sales. While the achievement of operational targets is a positive signal for company performance, these transactions are largely administrative and do not fundamentally alter the company's strategic outlook or financial health in a way that would warrant a strong buy or sell recommendation based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

Glaukos Corp, GKOS, Tomas Navratil, Chief Development Officer, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Acquisition, Tax Withholding, Operational Targets